Trump revives pharma tariffs, but includes loopholes

President Trump is reintroducing tariffs on pharmaceuticals, potentially imposing 100% charges on certain imported drugs. However, the "Section 232" national security levies will not apply to a broad range of medications. This selective application suggests that the overall impact on the pharmaceutical sector may be limited, as many products will remain exempt from the new tariffs. Analysts anticipate a low threat level to the industry due to these carefully crafted loopholes.